News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 12 - 17

First Patient Dosed in U.S. Pivotal Clinical Study of Utidelone for Breast Cancer Brain Metastases

On December 15, 2025, Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Huahao Zhongtian Biopharmaceutical Co., Ltd., announced the first patient dosing in its U.S. pivotal registrational clinical study (NCT06764940) evaluating Utidelone injection (UTD1), one of its core product's key overseas clinical pipelines, in combination with capecitabine for HER2-negative breast cancer brain metastases (BCBM).The study adopts a two-stage design and plans to enroll approximately 120 subjects. The primary endpoint is central nervous system objective response rate (CNS-ORR). Nearly 20 ...

浏览次数：0

查看详情>>

发布时间: 2025 - 12 - 16

Atom Therapeutics' ABP-745 Enters Global Phase II for Atherosclerosis

On December 16, 2025, Hangzhou Atom Therapeutics Co., Ltd. announced that its Phase II clinical trial application for ABP-745, a small molecule innovative drug in the anti-inflammatory field for the treatment of atherosclerosis, has been approved by the U.S. FDA. The company has initiated a multicenter Phase II clinical trial spanning the United States, China, and Australia, with Academician Ge Junbo, a cardiology expert at Zhongshan Hospital affiliated with Fudan University and an academician of the Chinese Academy of Sciences, serving as the Leading Principal Investigator.Atherosclerosis is ...

浏览次数：1

查看详情>>

发布时间: 2025 - 12 - 11

Genuine Biotech's Azvudine Receives Phase IIa Clinical Trial Approval for Hematologic Malignancies

Recently, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approved Genuine Biotech Co., Ltd.'s GEN-725 tablets (Azvudine) for a Phase IIa clinical trial in the treatment of hematologic malignancies. This approval marks an important step forward in Azvudine's clinical development in the field of hematologic oncology.Azvudine tablets are the first domestically approved nucleoside analog oral anti-HIV drug with independent intellectual property rights. The product has accumulated R&D and safety experience across indications including anti-HI...

浏览次数：0

查看详情>>

发布时间: 2025 - 12 - 08

Five Efung Portfolio Companies Selected for 2025 National Dual Drug Lists

On December 7, 2025, the National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security released the updated versions of the National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance along with the Commercial Health Insurance Innovative Drug List (2025).This marks the eighth adjustment to the NRDL since the establishment of the NHSA. The new list will be officially implemented nationwide on January 1 of the coming year. A total of 114 new drugs were successfully added, of which...

浏览次数：0

查看详情>>